Silo Pharma

Silo Pharma P/B

The P/B (Price-to-Book Ratio) of Silo Pharma (SILO) as of Nov 22, 2026 is 0.69. In the previous year, P/B (Price-to-Book Ratio) was 0.86 — a change of -20.16% (lower).

P/B

0.69

YoY

-20.16%

Last updated:

P/B (Price-to-Book Ratio) of Silo Pharma is 2025 0.69 . P/B (Price-to-Book Ratio) of Silo Pharma was 2024 0.86 . It decreases by -20.16% lower compared to the previous year.

The Silo Pharma P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
10.66 USD
Jan 1, 2019
-189.66 USD
Jan 1, 2020
3.39 USD
Jan 1, 2021
0.48 USD
Jan 1, 2022
0.42 USD
Jan 1, 2023
0.70 USD
Jan 1, 2024
0.86 USD
Jan 1, 2025
0.69 USD
The Silo Pharma P/B history
YEARP/BYoY
0.69-20.16%
0.86+22.70%
0.70+67.41%
0.42-12.36%
0.48-85.87%
3.39-101.79%
-189.66-1,879.84%
10.66+195.27%
3.61-29.64%
5.13+131.48%
2.22+20.90%
1.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Silo Pharma Stock analysis

What does Silo Pharma do? Silo Pharma Inc generates revenue through the development and licensing of intellectual property related to psychedelic-assisted therapies for neurological and mental health conditions. The company acquires and develops technology rights from universities and researchers, focusing on treatments for PTSD, Alzheimer's disease, and rare neurological disorders. It secures funding via sponsored research agreements, such as the one with Columbia University, which grants it an option to license patents and inventions involving Ketamine combinations for Alzheimer’s and stress-induced disorders. The primary customers are pharmaceutical companies seeking to expand their therapeutic portfolios with psychedelic-based treatments. The firm's products include intellectual property rights for psychedelic drug applications, particularly psilocybin and Ketamine-based therapies, targeting depression, mental health issues, and neurological disorders. These assets are developed through partnerships with academic institutions like Columbia University, where the company gains access to patented technologies for treating Alzheimer’s and stress-related conditions. The company does not sell products directly but licenses its IP to larger pharmaceutical firms for further development and commercialization. Silo Pharma targets the biopharmaceutical sector, specifically companies developing treatments for rare neurological disorders and mental health conditions. Its intellectual property is positioned to address unmet medical needs in PTSD, Alzheimer's, and depression, with a focus on psychedelic-assisted therapies. The company’s revenue model relies on licensing agreements and sponsored research deals, avoiding direct product sales. Columbia University remains a key partner in its IP acquisition strategy for Alzheimer's and stress disorder treatments. Silo Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Silo Pharma stock

P/B (Price-to-Book Ratio) of Silo Pharma is 0.69 in 2025.

P/B (Price-to-Book Ratio) of Silo Pharma changed from 0.86 to 0.69, representing a -20.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Silo Pharma since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Silo Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Silo Pharma

All Key Metrics — Silo Pharma